Therapies targeting the alarmins interleukin-33 and thymic stromal lymphopoietin are the next frontier in airway diseases. In addition to their role in adaptive immunity, emerging clinical data indicate these alarmins modulate innate immunity to address unmet needs in COPD and asthma. Read the article in full at err.ersjournals.com
No comments:
Post a Comment